Specialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 billion. The company’s management are clearly looking to bring cheer ...

Malvern-based Endo has approved $3.5 million in retention bonuses for its key executives as it works toward a merger with ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in ...

Ireland's Mallinckrodt has agreed a $1.3 billion deal to acquire Therakos, gaining rights to a technology that underpins cell-based immunotherapies. Therakos' platform is based on extracorporeal ...

Five presentations highlight TERLIVAZ research in adults with HRS with rapid reduction in kidney function,1 also known as HRS-AKI<sup ...

(RTTNews) - Specialty pharmaceutical companies Mallinckrodt plc and Endo, Inc. announced Thursday that they have entered into a definitive agreement to combine in a stock and cash transaction.

DUBLIN, April 10, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday ...

Pharmaceutical companies Mallinckrodt Pharmaceuticals Plc and Endo Inc. have signed an agreement to create a combined company worth $6.7 billion. This is reported in a joint press release. Under the ...

Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim view Thursday. Shares of Endo fell more ...

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Endo (OTCQX: NDOI) for possible breaches of fiduciary duty and other violations of law in its transaction with Mallinckrodt. Click here ...

DUBLIN, April 10, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025 ...